Skip to content

Study · Case report or series · n = 1 · 2022

3 results

Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report.

Zhang L, Yu WJ, Zhu H, Li HF, Qiao J

World journal of clinical cases1 Jul 2022Cited by 5 (Europe PMC)

PMID36158023 (opens in a new tab)PMCIDPMC9353915 (opens in a new tab)DOI10.12998/wjcc.v10.i21.7495 (opens in a new tab)PepBankPUB-36158023
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 27-year-old man with schizophrenia, type 2 diabetes and obesity on antipsychotics, two years of liraglutide gave stable and improved blood glucose levels.

    In plain wordsIn one man with schizophrenia and diabetes, two years of liraglutide was followed by stable, improved blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood glucose level
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Two years of liraglutide treatment resulted in stable blood glucose levels and weight loss in addition to a maintained stable mental status for a long time.
    4 context sentences
    Summary · context
    The biological activities of GLP-1 significantly improved glucose levels and body weight in the schizophrenia patient treated with antipsychotic medications.
    Summary · context
    A 27-year-old man with olanzapine and sodium valproate-treated disorganized schizophrenia was admitted to a diabetes outpatient clinic.
    Summary · context
    He was diagnosed with type 2 diabetes (fasting blood glucose, 20 mmol/L) and obesity (body mass index, 38.58 kg/m2).
    Summary · context
    The patient had been treated with glargine (40 IU/d) and metformin (1.5 g/d) and showed a poor response for 2 mo.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 27-year-old man with schizophrenia, type 2 diabetes and obesity on antipsychotics, two years of liraglutide was followed by weight loss.

    In plain wordsIn one man with schizophrenia and obesity, two years of liraglutide was followed by weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Two years of liraglutide treatment resulted in stable blood glucose levels and weight loss in addition to a maintained stable mental status for a long time.
    4 context sentences
    Summary · context
    The biological activities of GLP-1 significantly improved glucose levels and body weight in the schizophrenia patient treated with antipsychotic medications.
    Summary · context
    A 27-year-old man with olanzapine and sodium valproate-treated disorganized schizophrenia was admitted to a diabetes outpatient clinic.
    Summary · context
    He was diagnosed with type 2 diabetes (fasting blood glucose, 20 mmol/L) and obesity (body mass index, 38.58 kg/m2).
    Summary · context
    The patient had been treated with glargine (40 IU/d) and metformin (1.5 g/d) and showed a poor response for 2 mo.
  3. 03HumanCase report or seriesSafety outcome

    In a 27-year-old man with schizophrenia on antipsychotics, mental status stayed stable during two years of liraglutide treatment.

    In plain wordsIn one man with schizophrenia, mental state stayed stable for a long time during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeMental status stability
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Two years of liraglutide treatment resulted in stable blood glucose levels and weight loss in addition to a maintained stable mental status for a long time.
    3 context sentences
    Summary · context
    A 27-year-old man with olanzapine and sodium valproate-treated disorganized schizophrenia was admitted to a diabetes outpatient clinic.
    Summary · context
    He was diagnosed with type 2 diabetes (fasting blood glucose, 20 mmol/L) and obesity (body mass index, 38.58 kg/m2).
    Summary · context
    The patient had been treated with glargine (40 IU/d) and metformin (1.5 g/d) and showed a poor response for 2 mo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.